Focused On-demand Library for Epithelial splicing regulatory protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

RNA-binding motif protein 35A; RNA-binding protein 35A

Alternative UPACC:

Q6NXG1; A6NHA8; A8MPX1; E9PB47; Q2M2B0; Q499G3; Q6PJ86; Q9NXL8


Epithelial splicing regulatory protein 1, also known as RNA-binding motif protein 35A or RNA-binding protein 35A, plays a crucial role in mRNA splicing. It specifically regulates the formation of epithelial cell-specific isoforms, including FGFR2-IIIb, and is involved in the splicing of CD44, CTNND1, ENAH, crucial during the epithelial-to-mesenchymal transition. This protein's ability to bind specific sequences in mRNAs, particularly the GU-rich sequence motifs in the ISE/ISS-3 of FGFR2, underscores its significance in gene expression regulation.

Therapeutic significance:

Given its pivotal role in regulating splicing and expression of genes critical for inner ear development and auditory hair cell differentiation, Epithelial splicing regulatory protein 1 is directly linked to Deafness, autosomal recessive, 109. Understanding the role of this protein could open doors to potential therapeutic strategies for sensorineural deafness and vestibular dysplasia, offering hope for targeted interventions in genetic hearing loss conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.